Wuhan Hualong Biopharmaceutical Co., Ltd.

Wuhan Hualong Biopharmaceutical Co., Ltd., formerly known as Wuhan Meishan Biochemical Pharmaceutical Factory established in 1985, was restructured into the current company in 2000. It is a high-tech pharmaceutical enterprise integrating R&D, production and sales. It has more than 300 employees (more than 200 professional and technical personnel at colleges and above, and 36 practicing pharmacists). The company focuses on the field of injection drugs, especially bio-peptide products, and is one of the top three biochemical pharmaceutical companies in the country. The annual production capacity is about 90 million units. In 2004, it passed the GMP certification as a whole. In 2020, it was certified as a "high-tech enterprise" and won the bid for centralized procurement of national drugs in 2023. The core products of polypeptides include terlipressin injection, thymosin/thymosin injection for injection, somatostatin for injection, bone peptide injection, transfer factor injection, etc., covering cardiovascular and cerebrovascular, immune, digestive and other systemic therapeutic drugs.

Wuhan Hualong Biopharmaceutical Co., Ltd. is located at Zoumaling Street Hualongshengwu Science Park, Dongxihu District, Wuhan, China.

Main peptides produced: Thymopentin (TP-5).

Finished peptide dosage forms available.

Website: https://www.whualong.com